5月6日 - ** 药物开发商Actuate Therapeutics ACTU.O股价盘前上涨7.2%至10.6美元
** ACTU的实验性药物elraglusib与化疗联合使用，在一项中期试验中达到了主要目标，即与单独使用化疗相比，总生存期有显著改善。
** 该药物正在接受一线治疗转移性胰腺导管腺癌的试验，这种癌症始于胰腺导管，并已扩散到身体其他部位。
** 公司称，这种药物可帮助患者存活一年
** 截至收盘，ACTU股价累计上涨24.25
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.